ABK Biomedical Secures $35M: Advancing Imageable Embolotherapy for Cancer
October 16, 2025, 3:47 pm
ABK Biomedical secured $35M Series D funding, led by J.P. Morgan Life Sciences. This investment fuels Eye90 microspheres' clinical operations, commercialization, and manufacturing expansion. Eye90, an FDA Breakthrough Device, enhances Y90 radioembolization procedures. It targets benign and malignant hypervascular tumors, notably liver cancer. The funding validates ABK's innovative medical device technology. It propels their advanced imageable embolic solutions. This marks a significant step for patient care in interventional oncology. ABK's proprietary R&D and manufacturing capabilities underpin its market potential.
ABK Biomedical achieved a significant financial milestone. The company secured US$35 million in Series D funding. This investment drives forward its mission. It focuses on advanced imageable embolic medical devices. These innovations aim to improve treatment outcomes. They target patients with hypervascular tumors. This includes both benign and malignant conditions.
J.P. Morgan Life Sciences Private Capital led the funding round. This new investor brings considerable strategic expertise. Several existing backers also participated. F-Prime, Santé Ventures, and Eight Roads Ventures reaffirmed their commitment. An undisclosed major medical device company joined as well. The round was oversubscribed. This signals strong investor confidence in ABK's trajectory.
The newly acquired funds serve multiple critical purposes. They will support ongoing clinical operations. Preparations for commercializing Eye90 microspheres will accelerate. Eye90 microspheres is ABK's flagship product. The company will also boost product innovation and development efforts. Further, manufacturing and supply chain operations will expand. This scaling ensures robust support for Eye90 microspheres' future commercialization.
Eye90 microspheres represents a significant leap in medical technology. The U.S. Food and Drug Administration (FDA) granted it Breakthrough Device Designation. This status recognizes its potential. It offers a more effective treatment for life-threatening or debilitating conditions. Liver cancer stands as a primary focus. The product aims to enhance precision and visibility. It targets Yttrium-90 (Y90) radioembolization procedures. This is a growing segment within interventional oncology.
ABK Biomedical actively conducts pivotal clinical trials. The Route90 FDA Investigational Device Exemption (IDE) trial is underway. This study evaluates Eye90 microspheres' safety and efficacy. Researchers expect it to yield comprehensive data. This data set could be one of the most robust ever collected. Its scope covers the entire interventional oncology field. Strong clinical evidence supports regulatory approval. It also paves the way for wider market adoption.
The company's technology is designed to be highly differentiated. Eye90 microspheres aim for improved procedural visibility. They seek enhanced safety during treatments. Y90 therapies already show double-digit growth. ABK positions Eye90 as a superior solution. It combines innovative design with critical visual feedback.
ABK Biomedical's foundation rests on robust intellectual property. The company holds patents for inorganic polymer microspheres. It also protects unique administration systems. This intellectual capital drives its innovative edge. ABK maintains its own research and development facilities. It also operates its manufacturing plants. This end-to-end control ensures quality. It fosters continuous innovation in embolotherapy products. Mike Mangano leads the company. He serves as President and CEO. Under his guidance, ABK has made substantial progress. Its journey began with Series B funding in 2019.
The interventional oncology device market is dynamic. Y90 radioembolization is a rapidly expanding area. ABK Biomedical aims to capitalize on this growth. Its innovative Eye90 microspheres offer a clear advantage. The device provides physicians with unprecedented visibility. This directly translates to more precise interventions. Better targeting minimizes damage to healthy tissue. It maximizes therapeutic effect on tumors.
This funding round marks a pivotal moment for ABK Biomedical. It transitions the company from late-stage clinical development. It moves towards broad commercial availability. The strategic investment validates years of research. It supports rigorous development. The market for advanced embolic devices continues to expand. This expansion is fueled by an aging population. It is also driven by rising cancer incidences. ABK's technology addresses these critical needs.
The impact extends beyond financial returns. It promises significant advancements in patient care. Eye90 microspheres hold the potential to redefine treatment standards. It offers new hope for patients with hypervascular tumors. Liver cancer, a particularly aggressive disease, could see improved outcomes. The enhanced precision and visibility provided by Eye90 are crucial. They allow for more effective and safer procedures. This can lead to better quality of life for patients.
ABK Biomedical is not just developing products. It is shaping the future of interventional oncology. Its commitment to research is unwavering. Its manufacturing capabilities are robust. Its strategic partnerships are strong. This makes ABK a formidable player. The company stands ready to deliver on its promise. It aims for innovative solutions. It seeks to improve global patient health. This new capital infusion is a powerful accelerator. It speeds the journey towards that vital goal.
ABK Biomedical achieved a significant financial milestone. The company secured US$35 million in Series D funding. This investment drives forward its mission. It focuses on advanced imageable embolic medical devices. These innovations aim to improve treatment outcomes. They target patients with hypervascular tumors. This includes both benign and malignant conditions.
J.P. Morgan Life Sciences Private Capital led the funding round. This new investor brings considerable strategic expertise. Several existing backers also participated. F-Prime, Santé Ventures, and Eight Roads Ventures reaffirmed their commitment. An undisclosed major medical device company joined as well. The round was oversubscribed. This signals strong investor confidence in ABK's trajectory.
The newly acquired funds serve multiple critical purposes. They will support ongoing clinical operations. Preparations for commercializing Eye90 microspheres will accelerate. Eye90 microspheres is ABK's flagship product. The company will also boost product innovation and development efforts. Further, manufacturing and supply chain operations will expand. This scaling ensures robust support for Eye90 microspheres' future commercialization.
Eye90 microspheres represents a significant leap in medical technology. The U.S. Food and Drug Administration (FDA) granted it Breakthrough Device Designation. This status recognizes its potential. It offers a more effective treatment for life-threatening or debilitating conditions. Liver cancer stands as a primary focus. The product aims to enhance precision and visibility. It targets Yttrium-90 (Y90) radioembolization procedures. This is a growing segment within interventional oncology.
ABK Biomedical actively conducts pivotal clinical trials. The Route90 FDA Investigational Device Exemption (IDE) trial is underway. This study evaluates Eye90 microspheres' safety and efficacy. Researchers expect it to yield comprehensive data. This data set could be one of the most robust ever collected. Its scope covers the entire interventional oncology field. Strong clinical evidence supports regulatory approval. It also paves the way for wider market adoption.
The company's technology is designed to be highly differentiated. Eye90 microspheres aim for improved procedural visibility. They seek enhanced safety during treatments. Y90 therapies already show double-digit growth. ABK positions Eye90 as a superior solution. It combines innovative design with critical visual feedback.
ABK Biomedical's foundation rests on robust intellectual property. The company holds patents for inorganic polymer microspheres. It also protects unique administration systems. This intellectual capital drives its innovative edge. ABK maintains its own research and development facilities. It also operates its manufacturing plants. This end-to-end control ensures quality. It fosters continuous innovation in embolotherapy products. Mike Mangano leads the company. He serves as President and CEO. Under his guidance, ABK has made substantial progress. Its journey began with Series B funding in 2019.
The interventional oncology device market is dynamic. Y90 radioembolization is a rapidly expanding area. ABK Biomedical aims to capitalize on this growth. Its innovative Eye90 microspheres offer a clear advantage. The device provides physicians with unprecedented visibility. This directly translates to more precise interventions. Better targeting minimizes damage to healthy tissue. It maximizes therapeutic effect on tumors.
This funding round marks a pivotal moment for ABK Biomedical. It transitions the company from late-stage clinical development. It moves towards broad commercial availability. The strategic investment validates years of research. It supports rigorous development. The market for advanced embolic devices continues to expand. This expansion is fueled by an aging population. It is also driven by rising cancer incidences. ABK's technology addresses these critical needs.
The impact extends beyond financial returns. It promises significant advancements in patient care. Eye90 microspheres hold the potential to redefine treatment standards. It offers new hope for patients with hypervascular tumors. Liver cancer, a particularly aggressive disease, could see improved outcomes. The enhanced precision and visibility provided by Eye90 are crucial. They allow for more effective and safer procedures. This can lead to better quality of life for patients.
ABK Biomedical is not just developing products. It is shaping the future of interventional oncology. Its commitment to research is unwavering. Its manufacturing capabilities are robust. Its strategic partnerships are strong. This makes ABK a formidable player. The company stands ready to deliver on its promise. It aims for innovative solutions. It seeks to improve global patient health. This new capital infusion is a powerful accelerator. It speeds the journey towards that vital goal.